S3 Standard deviations and shrinkage estimates of interindividual random effects from the vedolizumab final population pharmacokinetic model ω† Parameter SD()* (%) ηshrink ETACLL 0.329 0.346 4.85 ETAVc 0.156 0.191 18.5 ETAVmax 0.542 1.05 48.5 CLL, clearance of linear elimination pathway; ETA, interindividual random effect; SD(), standard deviation of individual estimates; Vc, central compartment volume of distribution; Vmax, maximum elimination rate; ω, standard deviation of variance estimate; (%) = 100 · (1 - SD(η)/ω). ηshrink * Individual estimate used for the calculation of SD(η) was derived as the median of the individual’s random effect estimates from 4 Markov Chain Monte Carlo chains. ω estimate was derived from the median of the Bayesian posterior probability distributions from 4 Markov † Chain Monte Carlo chains. Covariate parameter estimates from the vedolizumab final population Table S4 pharmacokinetic model Bayesian 95% Credible Parameter Estimate* Interval* Continuous covariates effects (NULL effect = 0) Weight on 0.362 (0.299, CLL 0.427) Albumin 1.18 (1.24, on CLL 1.13) 0.0310 (0.0252, calprotectin 0.0365) on CLL CDAI 0.0515 (0.14, on CLL 0.0358) Partial 0.0408 (0.0336, Mayo score 0.115) on CLL Age on 0.0346 (-0.0788, CLL 0.01) Weight on 0.467 (0.423, Vc 0.511) Weight on 1 Fixed (1, 1) Vp Weight on 0.75 (0.75, Vmax Fixed 0.75)
S3 Standard deviations and shrinkage estimates of interindividual random effects from the vedolizumab final population pharmacokinetic model Parameter SD()* ω† ηshrink (%) ETACLL 0.329 0.346 4.85 ETAVc 0.156 0.191 18.5 ETAVmax 0.542 1.05 48.5 CLL, clearance of linear elimination pathway; ETA, interindividual random effect; SD(), standard deviation of individual estimates; Vc, central compartment volume of distribution; Vmax, maximum elimination rate; ω, standard deviation of variance estimate; ηshrink (%) = 100 · (1 - SD(η)/ω). * Individual estimate used for the calculation of SD(η) was derived as the median of the individual’s random effect estimates from 4 Markov Chain Monte Carlo chains. † ω estimate was derived from the median of the Bayesian posterior probability distributions from 4 Markov Chain Monte Carlo chains. Table S4 Covariate parameter estimates from the vedolizumab final population pharmacokinetic model Parameter Estimate* Bayesian 95% Credible Interval* Continuous covariates effects (NULL effect = 0) Weight on CLL 0.362 (0.299, 0.427) Albumin on CLL 1.18 (1.24, 1.13) calprotectin on CLL 0.0310 (0.0252, 0.0365) CDAI on CLL 0.0515 (0.14, 0.0358) Partial Mayo score on CLL 0.0408 (0.0336, 0.115) Age on CLL 0.0346 (-0.0788, 0.01) Weight on Vc 0.467 (0.423, 0.511) Weight on Vp 1 Fixed (1, 1) Weight on Vmax 0.75 Fixed (0.75, 0.75)
APT-42-188-s006.docx